Afrezza Inhaled Insulin for Pediatric Diabetes

Afrezza Inhaled Insulin for Pediatric Diabetes
80%69%58%May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 21 • YES 62.0%May 22 • YES 62.0%May 24 • YES 76.2%May 27 • YES 66.4%
Mannkind Corporation ($MNKD)
No stock close$3.64$3.26$2.87May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 18 • MNKD $2.99May 19 • MNKD $2.96May 20 • MNKD $3.25May 21 • MNKD $3.31May 22 • MNKD $3.38May 26 • MNKD $3.53May 27 • MNKD $3.55

Will this trial show a positive result on change in HbA1c?

Paper Trading
Create account to trade
ClinicalNewsTrialPositionsReasoningOracle
YESPending Review78% confidenceGPT-5.5 (OpenAI)
Question
Will this trial show a positive result on change in HbA1c?
Found
Outcome Date
Summary

MannKind's public readout frames INHALE-1 as encouraging/clinically meaningful and says mITT HbA1c change met noninferiority, though the full ITT narrowly missed due to one nonadherent outlier.

Sources
Sponsorinvestors.mannkindcorp.com
MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza)

For the 26-week HbA1c endpoint, ITT exceeded the 0.4% margin, but mITT excluding one nonadherent outlier established noninferiority; leaders called outcomes encouraging and clinically meaningful.

Stats
Latest Run
Model
GPT-5.5 (OpenAI)
Runs
2 runs